Adenosine Therapeutics is a world leader in the development of novel pharmaceutical products that target adenosine receptor subtypes. The company's most advanced product is Apadenoson, a highly selective A2A agonist, which is in Phase III clinical development for use as a stress agent during cardiac imaging. The Company is also developing drugs for the treatment of asthma, diabetes, Parkinson's disease, cancer, ophthalmic disease and inflammatory indications such as sepsis, heart attack, ischemia-reperfusion injury, sickle cell crisis, vascular injury, arthritis, spinal cord injury, COPD, and inflammatory bowel disease.
Business Wire reports Adenosine Therapeutics, LLC, was purchased by Clinical Data. Read more »